Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $46
Benzinga · 11/09/2023 15:45
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $47 to $46.